Botfet / Company detail

IBRX

approvedQuality override

ImmunityBio, Inc.

biotech

Moat score74out of 100

Quality overrideApproved by fash — High conviction on regulatory moat (Anktiva FDA approval) + founder-led structure (Patrick Soon-Shiong). Force-approved despite quality fail (ROIC -56.95%, interest coverage -1.99). Re-screen when sell engine ships.

The numbers

Financial metrics

Quality gate and thesis context

Roic-57.0%

Gross Margin99.3%

Revenue Cagr231.9%

Fcf Conversion87.9%

Fcf Yield-3.7%

Interest Coverage-2.0x

Market Cap B$8.3B

PeNot available: not applicable loss making

Quality PassFail

Founder LedNo

Thesis AlignedYes

Moat Quant52

Why it may endure

Moat breakdown

Quant: 52 · Curator: 22

Market Share Stability6

Network Effects6

Pricing Power14

Regulatory Moat20

Switching Costs6

Conviction6/10

Leadership8/10

Vision8/10

← Back to the full screener